Matrix metalloproteinase (MMP)-7 in salivary gland cancer. 2010

Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
Department of Otorhinolaryngology, Head and Neck Surgery, University of Turku and Turku University Hospital, Turku, Finland.

BACKGROUND High levels of certain matrix metalloproteinases (MMPs) have been detected in various human cancers. The purpose of this study was to analyze the expression of MMP-7 in salivary gland cancer (SGC) by immunohistochemistry and to associate the results with the clinical data and the 10-year survival of the SGC patients. METHODS Immunohistochemistry for MMP-7 was performed in a series of 107 paraffin-embedded sections of SGC. The samples represent the entire SGC population in Finland from 1991-1996. Mortality follow-up ended December 31, 2006. RESULTS The study population of 107 patients consisted of 47 male and 60 female subjects, ranging in age at the time of diagnosis between 23 and 90 years. The minimum follow-up time was 10.6 years and the maximum 15.9 years. By age-adjusted analysis lower staining intensity was associated with worse overall survival of patients with acinic cell carcinoma (p = 0.047, HR 6.5, 95% Cl 1.0-41.7) and in mucoepidermoid carcinoma (p = 0.010, HR 9.3, 95% CI 1.7-50.0). Low staining intensity was also associated with worse disease-specific survival of patients with acinic cell carcinoma (0-1 vs. 2-3; p = 0.047, HR 13.7, 1.0-200.0). VCI Ki-67 was an important prognostic factor for survival of the entire data set (p < 0.0001, HR 4.7, 95% Cl 2.3-9.8). CONCLUSIONS MMP-7 is associated with the prognosis of patients with acinic cell and mucoepidermoid carcinoma.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old

Related Publications

Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
June 2021, Clinical biochemistry,
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
September 2006, Medicinal chemistry (Shariqah (United Arab Emirates)),
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
March 2010, Clinical chemistry and laboratory medicine,
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
October 2002, European journal of morphology,
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
June 2009, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
July 2024, Hepatology (Baltimore, Md.),
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
January 1991, Comptes rendus des seances de la Societe de biologie et de ses filiales,
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
January 2021, Pathology, research and practice,
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
March 2015, Frontiers of medicine,
Heikki Luukkaa, and Pekka Klemi, and Pirkko Hirsimäki, and Tero Vahlberg, and Atte Kivisaari, and Veli-Matti Kähäri, and Reidar Grénman
March 2009, Surgery,
Copied contents to your clipboard!